|
|
|
| home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA) |
|
|
 WHITE PAPERS |
|
PRA Health Sciences (PRA)
|
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
|
|
Governments, healthcare payers, and social and health reforms, combined
with the increased incidence of conditions such as cancer and diabetes
are paving the way for increased uptake of biologic medicines in
emerging markets. However, expensive biologic medicines can be
prohibitive to many patients, creating a high level of unmet clinical
need. At its best, the global expansion of biosimilars can mean a robust
and steady supply of existing and new drugs reaching far-flung patient
populations, but localized biosimilar drug developments, especially in
China and India, combined with a lack of robust pharmacovigilance
systems, threaten to derail the industry by putting patient health at
risk.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Evolution Summit Press Release
“Many clinical trials today face delays because of difficulties in
recruiting the required number of patients within the timeline. Sponsors
need to look at other regions outside the US and Western Europe, that
have access to a large pool of motivated patients, without compromising
quality or anything else,” says Roman Hrynchuk, Chief Operating Officer,
SanaClis.
SanaClis was a solution provider at the Marcus Evans Evolution Summit March 2020.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Formulation and Drug Delivery Series UK
8-9 July 2020, Oxford Global
This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >> |
|
|
|
